1. Home
  2. EXK vs KOD Comparison

EXK vs KOD Comparison

Compare EXK & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endeavour Silver Corporation (Canada)

EXK

Endeavour Silver Corporation (Canada)

HOLD

Current Price

$7.82

Market Cap

2.3B

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$41.41

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXK
KOD
Founded
1981
2009
Country
Canada
United States
Employees
590
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
EXK
KOD
Price
$7.82
$41.41
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$13.94
$35.43
AVG Volume (30 Days)
5.2M
787.2K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.59
N/A
Revenue Next Year
$17.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.91
$6.21
52 Week High
$15.15
$47.84

Technical Indicators

Market Signals
Indicator
EXK
KOD
Relative Strength Index (RSI) 44.75 55.56
Support Level $7.20 $39.37
Resistance Level $8.43 $46.72
Average True Range (ATR) 0.39 2.96
MACD 0.04 -0.04
Stochastic Oscillator 40.82 60.79

Price Performance

Historical Comparison
EXK
KOD

About EXK Endeavour Silver Corporation (Canada)

Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: